Bristol-Myers Squibb Company
COMBINATION OF ANTI-LAG-3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES TO TREAT TUMORS
Last updated:
Abstract:
Provided are methods for clinical treatment of tumors (e.g., advanced solid tumors) using an anti-LAG-3 antibody in combination with an anti-PD-1 antibody.
Status:
Application
Type:
Utility
Filling date:
5 Apr 2019
Issue date:
27 Feb 2020